Answers are grounded in this paper and cite their sources.
Background: F-fluorodeoxyglucose positron emission tomography (FDG-PET) is recommended for diagnosis and evaluation of therapy in patients with cardiac sarcoidosis (CS). Objectives: FDG uptake parameters were investigated semi-quantitatively in biopsy-proven CS at time of diagnosis (CSD) and during immunosuppressive therapy (CST) and in controls. Methods: We studied 11 patients with endomyocardial biopsy-proven CS and 15 controls. FDG uptake was assessed as myocardial-to-background ratio (MBR) of standardized uptake values in the 17-segment model and right ventricle in relation to clinical baseline parameters and changes during follow-up (FU). Results: MBRs per cardiac segment in controls were below 2.1 in all control patients. In CSD, median MBR was 2.4 (IQR 1.3; 4.0), highest septal and anterobasal. In CST, median MBR was 1.5 (IQR 1.1; 1.7) with a significant reduction of mean MBRs from baseline per cardiac segment (z -9.5, p < 0.001). Patients with clinical progress showed higher MBRs and more affected cardiac segments before therapy (n = 2, MBR 4.3 ± 3.0, 18.0 ± 0) than patients with stable disease (n = 5, MBR 2.8 ± 1.2, 14.4 ± 4.6) or clinical improvement (n = 4, MBR 2.6 ± 2.5, 8.0 ± 7.4, p = n.s.) Applying a new score based on mean MBR times number of involved segments showed highest values in patients with clinical progression. Conclusion: MBRs per cardiac segment can be used as a semiquantitative tool to evaluate FDG uptake in patients with CS with a cut-off ≥2.1 for relevant pathologic uptake. The clinical course may correlate with the number of affected cardiac segments and the MBRs per segment.
No takes yet. Share an insight, caveat, or question.
Ueberham et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: